Stockreport

Immunogen's AbbVie Deal: Key Insights For Investors And Traders [Seeking Alpha]

ImmunoGen, Inc.  (IMGN) 
Last immunogen, inc. earnings: 5/1 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.immunogen.com/investor-relations
PDF The likelihood of an overbid is low due to a high termination fee and the current state of the biotech industry. The deal is expected to close in the middle of 2024, [Read more]